Protocol No.: NN9535-4801

Efficacy and safety of once-weekly semaglutide s.c. 2.0 mg as add-on to dose-reduced insulin glargine vs titrated insulin glargine in participants with type 2 diabetes and overweight
Principal Investigator
Pilkerton, Courtney
Phase
III
Age Group
Adult
Applicable Disease Site
Diabetes
Participating Institutions
Health Sciences Center
West Virginia University
Contact
Kelly Meno, MSN
Clinical Research Specialist
Phone: +1 304-293-1436

View on ClinicalTrials.gov